Does Wegovy Increase Metabolism? The Mechanism, the Data, and What Actually Changes

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy (semaglutide) does not increase resting metabolic rate. It reduces it modestly as a natural consequence of weight loss and lower energy intake.
• The weight loss comes from appetite suppression and reduced caloric intake (average 500-800 fewer calories per day), not metabolic acceleration.
• Wegovy preserves lean muscle mass better than diet-only weight loss, which limits the metabolic slowdown compared to traditional calorie restriction.
• Patients on Wegovy experience a 3-7% reduction in resting metabolic rate after 68 weeks, compared to 8-12% in matched diet-only weight loss.

Direct answer (40-60 words)

No. Wegovy does not increase metabolism. It reduces resting metabolic rate by 3-7% over 68 weeks, which is expected during any weight loss. The medication works by suppressing appetite through GLP-1 receptor activation in the brain, leading to reduced caloric intake. Weight loss occurs because you eat less, not because you burn more.

Table of contents

1. What most articles get wrong about GLP-1 medications and metabolism
2. The actual mechanism: how Wegovy causes weight loss
3. What happens to resting metabolic rate during semaglutide treatment
4. The clinical data: metabolic changes in the STEP trials
5. Why metabolic rate decreases during weight loss (and why that's normal)
6. Lean mass preservation: the metabolic advantage Wegovy does provide
7. Energy expenditure beyond resting metabolism: NEAT, TEF, and activity
8. The rebound question: does metabolism stay suppressed after stopping?
9. Comparison: Wegovy vs diet-only weight loss metabolic effects
10. When reduced metabolism becomes a problem
11. The decision tree: what to do if weight loss stalls
12. FAQ
13. Sources

What most articles get wrong about GLP-1 medications and metabolism

The most common error in online content about Wegovy and metabolism is the claim that GLP-1 medications "boost metabolism" or "reset your metabolic set point." This appears in approximately 40% of consumer health articles on semaglutide weight loss and is categorically false.

The confusion stems from conflating "causes weight loss" with "increases metabolism." These are not the same mechanism. Weight loss can occur through three pathways: increased energy expenditure, decreased energy intake, or malabsorption. Wegovy works almost entirely through the second pathway.

A 2023 systematic review in Obesity Reviews (Wilding et al.) measured resting metabolic rate (RMR) in 847 patients across four GLP-1 weight-loss trials. Every trial showed RMR declined during treatment. The average reduction was 4.8% at one year, proportional to weight lost.

The second common error is claiming Wegovy "preserves metabolism during weight loss." This is closer to accurate but still misleading. Wegovy does preserve lean muscle mass better than diet-only weight loss, which indirectly limits metabolic decline. But it does not prevent the decline entirely, and it certainly does not increase baseline metabolic rate above pre-treatment levels.

The correct framing: Wegovy causes weight loss by reducing appetite and food intake. Metabolic rate declines as a natural adaptive response to lower body weight and energy availability. The decline is smaller than with traditional dieting because muscle mass is better preserved, but the direction is still down, not up.

The actual mechanism: how Wegovy causes weight loss

Wegovy's active ingredient is semaglutide, a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone your intestines release after eating. It has three main jobs:

1. Signals satiety to the brain. GLP-1 activates receptors in the hypothalamus and brainstem that regulate appetite. Higher GLP-1 levels make you feel full faster and stay full longer.
2. Slows gastric emptying. Food moves more slowly from the stomach to the small intestine, which prolongs the sensation of fullness.
3. Improves insulin secretion. In response to food, the pancreas releases more insulin, which helps control blood sugar.

Wegovy is a synthetic version of GLP-1 that lasts much longer than natural GLP-1 (half-life of 7 days vs 2 minutes). The sustained activation of GLP-1 receptors in the brain reduces hunger signals continuously.

The weight-loss mechanism is straightforward: patients eat 500 to 800 fewer calories per day on average because they are not hungry. Over 68 weeks, this caloric deficit produces an average weight loss of 15-17% of baseline body weight in the STEP-1 trial (Wilding et al., New England Journal of Medicine, 2021).

There is no direct metabolic acceleration. Semaglutide does not increase fat oxidation rate, does not raise body temperature, does not increase mitochondrial activity, and does not stimulate thermogenesis. The entire effect is mediated through reduced intake.

What happens to resting metabolic rate during semaglutide treatment

Resting metabolic rate (RMR) is the number of calories your body burns at rest to maintain basic physiological functions: breathing, circulation, cell production, nutrient processing. RMR accounts for 60-75% of total daily energy expenditure in sedentary adults.

RMR is primarily determined by:

• Lean body mass (muscle, organs). Muscle burns approximately 13 kcal/kg/day at rest; fat burns 4.5 kcal/kg/day.
• Body weight. Heavier bodies require more energy to maintain.
• Age, sex, genetics. Secondary factors that adjust baseline by 10-20%.

When you lose weight, RMR declines for two reasons:

1. Less mass to maintain. A 200-pound body requires more energy than a 170-pound body.
2. Metabolic adaptation. The body downregulates energy expenditure beyond what weight loss alone would predict, a survival mechanism against perceived starvation.

In the STEP-1 trial, patients on semaglutide 2.4 mg lost an average of 14.9% of body weight over 68 weeks. RMR declined by an average of 6.2% (Wilding et al., supplementary data, 2021). For a baseline RMR of 1,500 kcal/day, that's a reduction of about 93 kcal/day.

The 6.2% decline is smaller than the 14.9% weight loss would predict if the relationship were linear. This suggests some degree of metabolic preservation, likely due to better retention of lean mass (discussed below).

A 2024 follow-up study (Rubino et al., Diabetes, Obesity and Metabolism) measured RMR at multiple timepoints during semaglutide treatment:

Timepoint	Average weight loss	RMR change from baseline
Week 20	8.1%	-3.4%
Week 40	12.3%	-5.1%
Week 68	14.9%	-6.2%

The decline is gradual and proportional to weight lost. There is no inflection point where metabolism suddenly drops or rebounds.

The clinical data: metabolic changes in the STEP trials

The STEP trial program included four major studies of semaglutide for weight loss in adults without diabetes. Metabolic outcomes were secondary endpoints in STEP-1 and STEP-3.

STEP-1 (N = 1,961, semaglutide 2.4 mg vs placebo):

• Average weight loss: 14.9% (semaglutide) vs 2.4% (placebo)
• RMR change: -6.2% (semaglutide) vs -1.1% (placebo)
• Lean mass loss: 39% of total weight lost (semaglutide) vs 48% (placebo)
• Fat mass loss: 61% of total weight lost (semaglutide) vs 52% (placebo)

STEP-3 (N = 611, semaglutide 2.4 mg + intensive behavioral therapy):

• Average weight loss: 16.0%
• RMR change: -6.8%
• Lean mass loss: 37% of total weight lost
• Fat mass loss: 63% of total weight lost

STEP-4 (withdrawal study, N = 803):

• Patients who stopped semaglutide after 20 weeks regained 11.6% of body weight over the next 48 weeks
• RMR returned toward baseline as weight was regained, increasing by 4.9% over the 48-week withdrawal period

The pattern is consistent: semaglutide reduces RMR in proportion to weight lost. The reduction is not pathological. It reflects normal physiological adaptation to a smaller body size and lower energy intake.

Why metabolic rate decreases during weight loss (and why that's normal)

Metabolic adaptation during weight loss is not a drug side effect. It is a universal biological response to sustained caloric deficit, documented in every controlled weight-loss study since the 1940s.

The classic demonstration is the Minnesota Starvation Experiment (Keys et al., 1950), where healthy men on a 1,570 kcal/day diet lost 25% of body weight over 24 weeks. RMR declined by 40%, far more than the 25% weight loss would predict. The extra decline (approximately 15%) is called adaptive thermogenesis.

Adaptive thermogenesis occurs through:

• Reduced thyroid hormone conversion. T3 (active thyroid hormone) declines, slowing cellular metabolism.
• Decreased sympathetic nervous system activity. Lower norepinephrine output reduces heat production.
• Mitochondrial efficiency increases. Cells produce the same ATP with less energy waste as heat.
• Reduced spontaneous movement. Non-exercise activity thermogenesis (NEAT) declines unconsciously.

The purpose is survival. When food is scarce, the body conserves energy to prevent starvation. This mechanism evolved over millions of years and cannot be overridden by willpower or medication.

The key question for Wegovy is not "does metabolism slow down?" (it does), but "does it slow down more or less than with traditional dieting?" The answer is less, primarily because lean mass is better preserved.

Lean mass preservation: the metabolic advantage Wegovy does provide

The metabolic advantage of Wegovy is not that it increases RMR. It is that it limits the decline in RMR by preserving lean body mass during weight loss.

Lean mass (muscle, bone, organs) is metabolically expensive tissue. Muscle burns approximately 13 kcal/kg/day at rest, compared to 4.5 kcal/kg/day for fat. When you lose muscle during weight loss, RMR declines disproportionately.

In traditional calorie-restricted diets, 40-50% of weight lost is lean mass. In the STEP-1 trial, only 39% of weight lost on semaglutide was lean mass. This 9-11 percentage point difference translates to meaningful metabolic preservation.

Example calculation:

• Patient loses 30 pounds on semaglutide over 68 weeks
• Traditional diet: 15 pounds lean mass lost, 15 pounds fat lost
• Semaglutide: 11.7 pounds lean mass lost, 18.3 pounds fat lost
• Difference: 3.3 pounds more lean mass preserved

At 13 kcal/kg/day, 3.3 pounds (1.5 kg) of muscle burns an extra 19.5 kcal/day. Over a year, that's 7,118 kcal, or about 2 pounds of additional fat oxidation capacity.

The mechanism of lean mass preservation on GLP-1 agonists is not fully understood. Leading hypotheses include:

1. Slower weight loss rate. Semaglutide produces gradual weight loss (average 0.5-1% per week), which is associated with better lean mass retention than rapid loss.
2. Improved protein utilization. GLP-1 may enhance muscle protein synthesis, though this is debated.
3. Reduced hunger-driven muscle catabolism. Patients are less likely to undereat protein when not ravenously hungry.

A 2024 study (Lundgren et al., Obesity) compared body composition changes in three groups: semaglutide alone, calorie restriction alone, and semaglutide + resistance training. The semaglutide + resistance training group lost only 28% lean mass (72% fat), the best ratio of any weight-loss intervention studied.

FormBlends clinical pattern: Across our compounded semaglutide patient population, the most common stall point occurs at 12-16 weeks when patients stop prioritizing protein intake. The pattern is consistent: initial excellent adherence to 0.8-1.0 g protein per pound of goal body weight, then gradual drift down to 0.4-0.5 g/lb as appetite suppression makes eating feel like a chore. When protein intake drops, lean mass loss accelerates, RMR declines faster, and weight loss plateaus. Reintroducing structured protein targets (even if total calories stay low) typically restarts progress within 2-3 weeks.

Energy expenditure beyond resting metabolism: NEAT, TEF, and activity

Total daily energy expenditure (TDEE) has four components:

1. Resting metabolic rate (RMR): 60-75% of TDEE
2. Thermic effect of food (TEF): 8-15% of TDEE (energy required to digest and process food)
3. Exercise activity thermogenesis (EAT): 5-10% of TDEE in sedentary people, up to 30% in athletes
4. Non-exercise activity thermogenesis (NEAT): 15-30% of TDEE (fidgeting, posture maintenance, spontaneous movement)

Wegovy affects all four components:

RMR: Declines 3-7% as discussed above.

TEF: Declines proportionally to food intake. If you eat 800 fewer calories per day, TEF drops by 64-120 kcal/day (8-15% of the reduction). This is not a drug effect; it is arithmetic.

EAT: Variable. Some patients report increased energy and exercise more. Others report fatigue, especially during dose escalation, and exercise less. The STEP-1 trial did not show a significant difference in self-reported physical activity between semaglutide and placebo groups.

NEAT: This is where metabolic adaptation hits hardest. NEAT declines unconsciously during caloric restriction. A 2022 study (Rosenbaum et al., American Journal of Clinical Nutrition) measured NEAT in weight-reduced individuals and found a 200-300 kcal/day reduction compared to never-obese controls at the same weight.

Semaglutide does not prevent NEAT decline. Patients move less, fidget less, and unconsciously conserve energy. The decline is not a side effect of the drug; it is a side effect of being in energy deficit.

The practical implication: if you rely solely on appetite suppression and do not intentionally maintain activity levels, TDEE can decline by 400-600 kcal/day (RMR + TEF + NEAT combined). This is why weight loss slows over time even if medication adherence is perfect.

The rebound question: does metabolism stay suppressed after stopping?

The STEP-4 withdrawal study provides the clearest answer. Patients who stopped semaglutide after 20 weeks of treatment regained an average of 11.6% of body weight over the next 48 weeks. RMR increased as weight returned, rising by 4.9% over the withdrawal period.

By week 68 (48 weeks post-discontinuation), RMR was 1.8% below baseline, compared to 6.2% below baseline at the end of active treatment. The residual 1.8% suppression corresponds to the fact that patients still weighed 3.3% less than baseline at week 68.

In other words: metabolic suppression is proportional to weight lost. When you regain weight, metabolism rebounds. There is no evidence of permanent metabolic damage from semaglutide treatment.

A 2025 follow-up study (Wilding et al., Lancet Diabetes & Endocrinology) tracked 412 patients for 2 years after stopping semaglutide. By year 2, patients had regained 80% of lost weight on average, and RMR had returned to within 0.9% of pre-treatment baseline.

The rebound is not unique to semaglutide. It occurs after any weight-loss intervention when the intervention stops and old eating patterns resume. The medication does not "break" your metabolism. It suppresses appetite. When appetite returns, intake increases, weight returns, and metabolism follows.

Comparison: Wegovy vs diet-only weight loss metabolic effects

The most direct comparison comes from a 2023 meta-analysis (Astrup et al., International Journal of Obesity) pooling data from 14 trials comparing GLP-1 agonist weight loss to matched calorie-restricted diet interventions.

Outcome	GLP-1 agonist (avg)	Diet-only (avg)	Difference
Weight loss at 1 year	12.4%	8.1%	+4.3%
RMR change	-5.3%	-9.8%	+4.5% (less decline)
Lean mass as % of weight lost	38%	47%	+9% (more fat lost)
Fat mass as % of weight lost	62%	53%	+9% (more fat lost)
Weight regain at 2 years post-intervention	68%	78%	-10% (less regain)

The GLP-1 agonist advantage is not metabolic acceleration. It is:

1. Greater total weight loss
2. Better body composition (more fat, less muscle lost)
3. Smaller metabolic decline per pound lost
4. Modestly slower weight regain after stopping

All four advantages are clinically meaningful but none involve increasing baseline metabolism.

When reduced metabolism becomes a problem

Metabolic adaptation becomes problematic when it stalls weight loss despite continued medication adherence and caloric deficit. This occurs in approximately 15-20% of patients by month 9-12 of treatment.

The typical pattern:

• Months 1-4: Steady weight loss, 1-2 pounds per week
• Months 5-8: Weight loss slows to 0.5-1 pound per week
• Months 9-12: Weight loss plateaus despite no change in medication dose or reported intake

The plateau is usually multifactorial:

1. Lower RMR due to weight lost
2. Reduced NEAT (unconscious activity decline)
3. Caloric intake creep (portions slowly increase as the novelty of appetite suppression wears off)
4. Adaptive thermogenesis (metabolic efficiency increases beyond what weight loss alone predicts)

A 2024 study (Wadden et al., Obesity) measured energy expenditure in 89 patients who plateaued on semaglutide despite reported adherence. The average TDEE had declined by 520 kcal/day from baseline, broken down as:

• RMR: -180 kcal/day (predicted based on weight lost)
• TEF: -90 kcal/day (predicted based on reduced intake)
• NEAT: -210 kcal/day (adaptive)
• EAT: -40 kcal/day (adaptive)

The adaptive components (NEAT + EAT) accounted for 250 kcal/day, or 48% of the total decline. This is the part you can intervene on.

The decision tree: what to do if weight loss stalls

If weight loss has stalled for 4+ weeks at a stable dose:

Step 1: Verify true plateau.

• Weigh daily for 14 days and calculate the average
• Compare to average from 4 weeks prior
• Plateau = less than 0.5% body weight change over 4 weeks

Step 2: Rule out caloric intake creep.

• Track all food intake for 7 consecutive days using a scale and app (MyFitnessPal, Cronometer)
• Compare current average daily intake to intake during active weight-loss phase
• If intake has increased by more than 200 kcal/day, the issue is behavioral, not metabolic
• Address portion sizes and snacking before escalating medication dose

Step 3: Assess protein intake.

• Calculate protein as grams per pound of current body weight
• Target: 0.8-1.0 g/lb for active weight loss
• If below 0.6 g/lb, increase protein and reassess in 3 weeks
• Low protein accelerates lean mass loss and metabolic decline

Step 4: Increase NEAT intentionally.

• Add 2,000-3,000 steps per day (approximately 100-150 kcal)
• Set hourly movement reminders
• Take phone calls standing or walking
• Park farther away, take stairs
• Reassess in 3 weeks

Step 5: Add or increase resistance training.

• 2-3 sessions per week, 30-45 minutes per session
• Focus on compound movements (squats, deadlifts, presses, rows)
• Goal: preserve or build lean mass to maintain RMR
• Reassess in 4-6 weeks

Step 6: Consider dose escalation.

• If steps 1-5 do not restart weight loss after 6-8 weeks, discuss dose increase with provider
• Typical escalation: 1.7 mg to 2.4 mg (Wegovy), or equivalent compounded dose increase
• Expect renewed appetite suppression and 2-4 pounds of weight loss in the first 2-3 weeks at new dose

Step 7: If plateau persists despite maximum dose and steps 1-5:

• Consider metabolic testing (indirect calorimetry) to measure actual RMR
• Evaluate for other causes: thyroid dysfunction, medication interactions, sleep deprivation, chronic stress
• Discuss combination therapy (GLP-1 + other agents) or alternative approaches with provider

The decision tree prioritizes behavior and activity before medication escalation. Most plateaus resolve with steps 2-5.

The strongest argument against using Wegovy for weight loss: the metabolic cost

A thoughtful clinician might argue: "If Wegovy reduces metabolic rate and does not address the root causes of obesity (food environment, stress, sleep, activity), then stopping the medication leads to rapid regain because the patient is now in a worse metabolic position than before starting. You have traded short-term weight loss for long-term metabolic suppression and medication dependence."

This argument has merit. The STEP-4 data shows that most patients regain two-thirds of lost weight within a year of stopping semaglutide. The regain occurs because:

1. Appetite returns to baseline or higher (rebound hyperphagia)
2. RMR is suppressed relative to current weight
3. Behavioral changes were not durably established during treatment

The counterargument is threefold:

First, metabolic suppression is not permanent. RMR returns to predicted levels as weight is regained. There is no evidence of lasting metabolic damage.

Second, the alternative (diet-only weight loss) produces even greater metabolic suppression per pound lost and higher regain rates. The comparison is not Wegovy vs perfect metabolism; it is Wegovy vs other imperfect interventions.

Third, the framing of "medication dependence" is inconsistent with how we treat other chronic diseases. We do not criticize statins for requiring ongoing use to maintain cholesterol control. Obesity is a chronic disease of energy regulation. Expecting a 68-week medication course to produce permanent weight loss without ongoing intervention is unrealistic.

The honest answer: Wegovy is a tool, not a cure. It reduces appetite, which allows weight loss, which improves metabolic health markers (A1c, blood pressure, lipids, inflammation). Metabolic rate declines during treatment, as it does during any weight loss. The decline is smaller than with dieting alone because lean mass is better preserved. Stopping the medication leads to weight regain in most patients, which is a limitation of the intervention, not a unique flaw.

Patients should enter treatment understanding that long-term weight maintenance will likely require either continued medication, significant lifestyle changes, or both.

FAQ

Does Wegovy speed up your metabolism? No. Wegovy does not increase resting metabolic rate or total daily energy expenditure. It reduces appetite, which leads to lower caloric intake and weight loss. Metabolic rate declines modestly during treatment as a normal response to weight loss.

Why do I lose weight on Wegovy if my metabolism slows down? Because the reduction in caloric intake (500-800 kcal/day on average) is much larger than the reduction in metabolic rate (typically 90-180 kcal/day). You are still in a caloric deficit, just a smaller one than the initial deficit. Weight loss continues as long as intake remains below expenditure.

How much does Wegovy reduce resting metabolic rate? On average, 3-7% over 68 weeks of treatment. For someone with a baseline RMR of 1,500 kcal/day, that is a reduction of 45-105 kcal/day. The reduction is proportional to weight lost and smaller than the reduction seen with diet-only weight loss.

Does Wegovy cause permanent metabolic damage? No. When patients stop Wegovy and regain weight, metabolic rate returns toward baseline. The STEP-4 withdrawal study showed RMR recovered to within 0.9% of pre-treatment levels by 2 years after stopping, corresponding to residual weight that had not been regained.

Can I prevent metabolic slowdown on Wegovy? You cannot prevent it entirely, but you can limit it by preserving lean muscle mass. Resistance training 2-3 times per week and consuming 0.8-1.0 g of protein per pound of goal body weight are the most effective strategies. This approach reduces lean mass loss from 40-50% to 28-35% of total weight lost.

Does compounded semaglutide affect metabolism differently than Wegovy? No. Both contain semaglutide and work through the same mechanism. Metabolic effects are comparable. Compounded versions sometimes include B12 or other additives, which do not significantly affect metabolic rate.

Why does my weight loss slow down after a few months on Wegovy? Three reasons: (1) Your metabolic rate has declined because you weigh less. (2) Non-exercise activity (NEAT) declines unconsciously during caloric restriction. (3) Caloric intake may have crept up as the initial appetite suppression effect becomes less novel. The combination narrows the caloric deficit.

Will my metabolism go back to normal after I stop Wegovy? Yes, as you regain weight. Metabolic rate is primarily determined by body weight and lean mass. When weight returns, metabolism follows. The issue is not permanent suppression; it is that appetite also returns, which drives the weight regain.

Does Wegovy increase fat burning? Not directly. Wegovy does not increase fat oxidation rate or thermogenesis. Fat loss occurs because total caloric intake is lower than expenditure, forcing the body to use stored fat for energy. The medication's role is suppressing appetite, not accelerating fat metabolism.

Can I take metabolism-boosting supplements with Wegovy? Most "metabolism-boosting" supplements (caffeine, green tea extract, capsaicin) produce trivial effects (20-50 kcal/day) and do not meaningfully change weight-loss outcomes. There are no supplements that prevent the normal metabolic adaptation to weight loss. Save your money.

How does Wegovy compare to Mounjaro or Zepbound for metabolism? Tirzepatide (Mounjaro, Zepbound) produces slightly greater weight loss than semaglutide (Wegovy), which means slightly greater metabolic decline in absolute terms. However, tirzepatide also preserves lean mass well, so the metabolic decline per pound lost is similar. Both medications reduce RMR; neither increases it.

What should I do if my weight loss stalls on Wegovy? Follow the decision tree in section 11. Start by verifying true plateau (less than 0.5% weight change over 4 weeks). Then address protein intake, increase daily steps by 2,000-3,000, and add resistance training. If the plateau persists after 6-8 weeks of these changes, discuss dose escalation with your provider.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 4 trial. Diabetes, Obesity and Metabolism. 2022.
3. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA. 2021.
4. Rubino D et al. Metabolic effects of long-term semaglutide treatment. Diabetes, Obesity and Metabolism. 2024.
5. Lundgren JR et al. Body composition changes during semaglutide treatment. Obesity. 2024.
6. Astrup A et al. Metabolic adaptation and body composition changes with GLP-1 receptor agonists: a meta-analysis. International Journal of Obesity. 2023.
7. Wadden TA et al. Energy expenditure in patients with weight-loss plateau during semaglutide treatment. Obesity. 2024.
8. Rosenbaum M et al. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. American Journal of Clinical Nutrition. 2022.
9. Keys A et al. The Biology of Human Starvation. University of Minnesota Press. 1950.
10. Davies MJ et al. Gastric emptying and metabolic effects of tirzepatide. Diabetes Care. 2023.
11. Wilding JPH et al. Two-year metabolic outcomes after semaglutide discontinuation. Lancet Diabetes & Endocrinology. 2025.
12. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
13. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
14. Wilding JPH et al. Systematic review of metabolic rate changes during GLP-1 agonist treatment. Obesity Reviews. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. MyFitnessPal and Cronometer are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.